Salvage therapy with bortezomib and dexamethasone in elderly patients with relapsed/refractory multiple myeloma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Salvage therapy with bortezomib and dexamethasone in elderly patients with relapsed/refractory multiple myeloma

Published:2015-11 Issue:10 Volume:26 Page:1078-1082
ISSN:0959-4973
Container-title:Anti-Cancer Drugs
language:en
Short-container-title:

Author:

Castelli Roberto,Pantaleo Giuseppe,Gallipoli Paolo,Gidaro Antonio,Arquati Massimo,Wu Maddalena A.,Lambertenghi Deliliers Giorgio

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology (medical),Pharmacology,Oncology

Reference24 articles.

1. . Improved survival in multiple myeloma and the impact of novel therapies.;Kumar;Blood,2008

2. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents.;Chanan-Khan;J Clin Oncol,2010

3. . Clinical course of patients with relapsed multiple myeloma.;Kumar;Mayo Clin Proc,2004

4. Choosing treatment options for patients with relapsedrefractory multiple myeloma.;Castelli;Expert Rev Anticancer Ther,2014

5. Multiple myeloma.;Palumbo;N Engl J Med,2011

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incidence of Venous Thromboembolism in Multiple Myeloma Patients across Different Regimens: Role of Procoagulant Microparticles and Cytokine Release;Journal of Clinical Medicine;2022-05-11

2. Relapsed refractory multiple myeloma: a comprehensive overview;Leukemia;2019-08-27

3. Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies;Haematologica;2019-06-20

4. A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma;Critical Reviews in Oncology/Hematology;2018-01

5. Bortezomib, melphalan, and prednisone in elderly relapsed/refractory multiple myeloma patients: update of multicenter, open-label Phase 1/2 study;Leukemia & Lymphoma;2017-04-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3